Ipsen (XPAR:IPN) COGS-to-Revenue : 0.18 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Ipsen COGS-to-Revenue?

Ipsen's Cost of Goods Sold for the six months ended in Dec. 2023 was €301 Mil. Its Revenue for the six months ended in Dec. 2023 was €1,683 Mil.

Ipsen's COGS to Revenue for the six months ended in Dec. 2023 was 0.18.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ipsen's Gross Margin % for the six months ended in Dec. 2023 was 82.10%.

Ipsen COGS-to-Revenue Historical Data

The historical data trend for Ipsen's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen COGS-to-Revenue Chart

Ipsen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.18

0.16

0.17

Ipsen Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.16	0.16	0.17	0.17	0.18

Ipsen COGS-to-Revenue Calculation

Ipsen's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	571.2	/	3306.4
	=	0.17

Ipsen's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	301.3	/	1683.3
	=	0.18

Ipsen (XPAR:IPN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ipsen's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	301.3 / 1683.3
	=	82.10 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Ipsen COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ipsen's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (XPAR:IPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (XPAR:IPN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

IPSEY:USA IPSEF:USA 0MH6:UK I7G:Germany

Address

65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100

Website

https://www.ipsen.com

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.